Sterling Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Sterling Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.86K	Buy	544 +157	+41%	+$791	﹤0.01%	2892
2026 Q1	$1.44K	Sell	387 -273	-41%	-$1.89K	﹤0.01%	3042
2025 Q4	$5.4K	Buy	660 +81	+14%	+$599	﹤0.01%	2871
2025 Q3	$4.26K	Buy	579 +323	+126%	+$2.44K	﹤0.01%	2806
2025 Q2	$2.08K	Sell	256 -179	-41%	-$1.21K	﹤0.01%	2906
2025 Q1	$3.06K	Sell	435 -332	-43%	-$2.06K	﹤0.01%	2401
2024 Q4	$5.7K	Buy	767 +699	+1,028%	+$4.46K	﹤0.01%	2405
2024 Q3	$335	Buy	+68	New	+$355	﹤0.01%	3005

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Sterling Capital Management's LFCR Position: Q2 2026 in Review

Sterling Capital Management increased its Lifecore Biomedical (LFCR) stake by 41% in Q2 2026, buying an estimated $791 and bringing the position to 544 shares worth $2.86K. The position accounts for ﹤0.01% of the portfolio, ranked #2892.

Sterling Capital Management first reported a position in LFCR in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.7K in Q4 2024. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

Sterling Capital Management held 544 shares of Lifecore Biomedical worth $2.86K as of Q2 2026.
Sterling Capital Management bought 157 Lifecore Biomedical shares in Q2 2026, an estimated $791.
Lifecore Biomedical made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2892 holding.
Sterling Capital Management first reported a position in Lifecore Biomedical in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Lifecore Biomedical position peaked at $5.7K in Q4 2024.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.